tbuckley/cabot-search huggingface dataset:
Abstract 350: Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
Authors: Han Zhu, Daniel Lee, Waliany Sarah, Francisco X Galdos, Jessica D’Addabbo, Michael B Fowler, Sunil Reddy, Wakelee Heather, Joel W Neal, Ronald Witteles, Holden T Maecker, Mark Davis, Patricia K NGUYEN, Sean M Wu
Journal: Circulation Research (2020)

Introduction: Immune checkpoint inhibitors (ICIs) are novel drugs that activate T cell-mediated anti-tumor response by blocking immune checkpoints such as PD-1 or CTLA-4, leading to improved cancer patient survival. Despite these benefits, ICIs can result in autoimmune side effects including fulminant myocarditis and heart failure. While ICI-induced myocarditis is characterized by myocardial T cell infiltration, the causal mechanisms remain unknown. We hypothesize that ICI-induced myocarditis is caused by cardiac-specific auto-antigens triggering clonal expansion of myocardial CD8+ T-cells, leading to T-cell mediated myocardial damage. Methods/Results: We have explored the ICI-induced inflammatory response in a mouse model of myocarditis induced by PD-1 knockout and in patients with ICI-induced myocarditis. PD-1 deficient-mice on a lupus-like autoimmune background (i.e. MRL/Pcd1-/- mice) develop spontaneous fatal myocarditis in 70% of animals by 5 weeks of age, with massive cardiac infiltration of CD8&gt;CD4+ T-cells. Likewise, patients with ICI-induced myocarditis have CD8&gt;CD4+ T-cell infiltrate in the heart. We have performed time-of-flight mass cytometry (CyTOF) to immunophenotype the T-cell subsets in the blood/myocardium of MRL/Pcd1-/- mice and in ICI-myocarditis patients. We have also conducted single cell sequencing of T-cell receptors (TCRs) from the blood +/- myocardial-derived T-cell samples of the mice and patients. Our preliminary results in ICI-myocarditis patients confirmed the previously reported CD8+ T-cell expansion in the blood and myocardium of myocarditis patients compared with healthy control. We are currently identifying candidate cardiac auto-antigen(s) responsible for this disease by performing Grouping Lymphocyte Interactions by Paratope Hotspots (GLIPH). Conclusion: Myocarditis is a serious and life-threatening complication of ICI treatment. By understanding the unique immune response present during ICI-induced myocarditis and the responsible cardiac auto-antigen(s) involved, we will pave the way for the development of adjuvant therapies that target these antigens and mitigate their deleterious effects.
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
Authors: Anup S. Pathania, Philip Prathipati, Bakrudeen AA. Abdul, Srinivas Chava, Santharam S. Katta, Subash C. Gupta, Pandu R. Gangula, Manoj K. Pandey, Donald L. Durden, Siddappa N. Byrareddy, Kishore B. Challagundla
Journal: Theranostics (2020)

The coronavirus disease 2019 is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals.COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes.The COVID-19 outbreak originated in Wuhan, China at the end of 2019.As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19.Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer.Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19.Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings.In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment.Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.
Phenotypic Plasticity Contributes to Maize Adaptation and Heterosis
Authors: Nannan Liu, Yuanhao Du, Marilyn L Warburton, Yingjie Xiao, Jianbing Yan
Journal: Molecular Biology and Evolution (2020)

Plant phenotypic plasticity describes altered phenotypic performance of an individual when grown in different environments. Exploring genetic architecture underlying plant plasticity variation may help mitigate the detrimental effects of a rapidly changing climate on agriculture, but little research has been done in this area to date. In the present study, we established a population of 976 maize F1 hybrids by crossing 488 diverse inbred lines with two elite testers. Genome-wide association study identified hundreds of quantitative trait loci associated with phenotypic plasticity variation across diverse F1 hybrids, the majority of which contributed very little variance, in accordance with the polygenic nature of these traits. We identified several quantitative trait locus regions that may have been selected during the tropical-temperate adaptation process. We also observed heterosis in terms of phenotypic plasticity, in addition to the traditional genetic value differences measured between hybrid and inbred lines, and the pattern of which was affected by genetic background. Our results demonstrate a landscape of phenotypic plasticity in maize, which will aid in the understanding of its genetic architecture, its contribution to adaptation and heterosis, and how it may be exploited for future maize breeding in a rapidly changing environment.
Genetic Inhibition of<i>PCSK9</i>and Liver Function
Authors: Antoine Rimbert, Sarra Smati, Wieneke Dijk, Cédric Le May, Bertrand Cariou
Journal: JAMA Cardiology (2020)

This study investigates associations of the lifelong genetic inhibition of PCSK9 with plasma liver enzymes and nonalcoholic fatty liver disease by using the loss-of-function variant PCSK9-p.Arg46Leu as a genetic instrument.
Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia
Authors: Bor-Sheng Ko, Yu-Fen Wang, Jeng-Lin Li, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien, Ting-Yu Chang, Chi-Chun Lee
Journal: Blood (2020)
The AML EBMT Cytogenetic Risk Score for Acute Myeloid Leukaemia (AML) Is Prognostic for Outcomes of Allogeneic Stem Cell (HSCT)
Authors: Yan Beauverd, Sarah Morin, Mitja Nabergoj, Caroline Stephan, Carmen De Ramon Ortiz, Anne-Claire Mamez, Elif Mahne, Anna Petropoulou, Federica Giannotti, Federico Simonetta, Christian Ayer, Benjamin Bruno, Laura Bounaix, Maria Anastasiou, Maria Mappoura, Thien-An Tran, Stavroula Masouridi-Levrat, Yves Chalandon
Journal: Blood (2020)
Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US
Authors: Ahmar Urooj Zaidi, Thokozeni Lipato, Ofelia A. Alvarez, Alexander Lonshteyn, Derek Weycker, Nhat Pham, Thomas E Delea, Irene Agodoa, Ze Cong, Nirmish Shah
Journal: Blood (2020)
Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome
Authors: Meera Mohan, Samantha Kendrick, Yadav Pandey, Richa Parikh, Phil Farmer, Mathew Kottarathara, Shadiqul Hoque, Angel Mitma, Sharmilan Thanendrarajan, Carolina D. Schinke, Guido Tricot, Maurizio Zangari, Frits van Rhee
Journal: Blood (2020)
Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission
Authors: Armin Ghobadi, Kahee A Mohammed, Rawan Faramand, Hagop M. Kantarjian, Elias Jabbour, Nicholas J. Short, Feng Gao, Geoffrey L Uy, Peter Westervelt, John F. DiPersio, Richard E. Champlin, Farhad Ravandi, Partow Kebriaei
Journal: Blood (2020)
Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study
Authors: Heinz Ludwig, Evangelos Terpos, María-Victoria Mateos, Mario Boccadoro, Bhuvan Kishore, Karthik Ramasamy, Sylvie Fernandez, Fabio Ferri, Nawal Bent-Ennakhil, Athanasios Zomas, François Gavini, Roman Hajek
Journal: Blood (2020)
Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations
Authors: Wynn Peterson, Rachel Martin, Brendan Carvalho, Jose Carvalho, Jeff Gadsden, Peter A. Kouides, David J. Kuter, Michelle Lavin, Natalia Rydz, Eliane Shore, Michelle Sholzberg
Journal: Blood (2020)
Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy
Authors: John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani
Journal: Blood (2020)
<i>Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia</i>
Authors: Gail J. Roboz, Daniel J. DeAngelo, David A. Sallman, Monica L. Guzman, Pinkal Desai, Hagop M. Kantarjian, Marina Konopleva, Nelli Bejanyan, Hany Elmariah, Francisco Javier Esteva, Andrew Garton, Kate Backhouse, Roman Galetto, Carrie Brownstein, Naveen Pemmaraju
Journal: Blood (2020)
Clonally Expanded Bone Marrow T Cells Show Effector Differentiation and Rarely Recognize Disease-Associated Antigens in Multiple Myeloma
Authors: Carlotta Welters, Meng-Tung Hsu, Christian Alexander Stein, Livius Penter, María Fernanda Lammoglia Cobo, Kerstin Dietze, Eric Blanc, Dieter Beule, Lars Bullinger, Julian Strobel, Holger Hackstein, Armin Gerbitz, Klaus Dornmair, Thomas Blankenstein, Leo Hansmann
Journal: Blood (2020)
Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma
Authors: Jillian Simard, Christopher Melani, Rahul Lakhotia, Michail S. Lionakis, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Lydia L. Chou, Matthias Holdhoff, Michael Glantz, John A. Butman, Andrea Nicole Lucas, Seth M. Steinberg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood (2020)
Abstract MP172: Y-chromosome Gene, Uty, Confers Male Protection Against Pulmonary Hypertension by Mediating Pro-inflammatory Chemokine Effects
Authors: Christine M Cunningham, Soban Umar, Min Li, Mitali Doshi, Gregoire Ruffenach, JASON HONG, Haley Hrncir, Arthur Arnold, Mansoureh Eghbali
Journal: Circulation Research (2020)

Background: Idiopathic pulmonary arterial hypertension (PAH) is a terminal vascular lung disease characterized by increased PA pressure resulting in right ventricular (RV) failure and death. For reasons largely unknown, PAH is up to 4x more prevalent in females. We published that the Y-Chromosome (Chrm) is protective against hypoxia (Hx)-induced pulmonary hypertension (PH) in mice and identified four Y-Chrm genes expressed in the lung. Here, we identify the protective Y-Chrm gene, investigate its mechanism and demonstrate a novel therapeutic approach. Methods and Results: To test the effect of Y-Chrm candidate genes on PH development, we knocked down (KD) each Y-Chrm gene via sequential intratracheal instillation of siRNA in the lungs of male mice exposed to Hx. KD of Y-Chrm gene Uty, but none of the other genes, resulted in more severe PH measured by increased RV systolic pressure (RVSP) and decreased pulmonary arterial acceleration time (PAAT) compared to control (n=4/group; RVSP: Uty-KD= 48.93mmHg, Control= 37.33mmHg, p=0.04; PAAT: Uty-KD= 11.88ms, Control= 14.43ms, p=0.01). RNAseq analysis (Uty-KD vs Control) revealed an increase in pro-inflammatory cytokines Cxcl9 (Log2FC: 1.3, p-adjusted=0.05) and Cxcl10 (Log2FC: 0.9, p-adjusted=0.002). We found Cxcl9/10 significantly upregulated in human PAH lungs vs healthy and female PAH lungs vs male (RT-qPCR). Fluorescent in-situ hybridization revealed Uty and Cxcl9/10 expression co-localized in CD68 + macrophages within the lung. Treatment of human pulmonary artery endothelial cells (PAEC) with Cxcl9/10 resulted in significantly increased apoptosis. We inhibited Cxcl9/10 activity in female rats 14 days post monocrotaline (MCT) injection by treating them with a small molecular inhibitor. Treated rats (n=6) had less severe PH than vehicle-treated controls (n=5) when measured 28-days post MCT (RVSP: Treated= 36.75mmHg, Vehicle=43.62 mmHg, p=0.03; PAAT: Treated= 26.7ms, Vehicle=20 ms, p=0.01; RV hypertrophy index (RV/(LV+IVS)): Treated= 0.48, Vehicle= 0.35, p=0.01). Conclusion: Y-Chrm gene, Uty, is protective against PH. Uty inhibition increases pro-inflammatory cytokines Cxcl9/10 which contribute to PAEC death. Inhibition of Cxcl9/10 activity may provide a novel therapy for the treatment of PH.
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Authors: Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, Samuel J Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison J Turner, Suzanne Carreira, Ruth Riisnaes, Laura Finneran, Emma Hall, Yuji Ishikawa, Kiyohiko Nakai, Nina Tunariu, Bristi Basu, Martin Kaiser, Juanita Suzanne Lopez, Anna Minchom, Johann S de Bono, Udai Banerji
Journal: The Lancet Oncology (2020)
Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
Authors: Bharat Nandakumar, David L. Murray, Angela Dispenzieri, Prashant Kapoor, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, David Dingli, Yi L. Hwa, Amie Fonder, Miriam A. Hobbs, Suzanne R. Hayman, John A. Lust, Nelson Leung, Ronald S. Go, Yi Lin, Wilson I Gonsalves, Taxiarchis Kourelis, Rahma M Warsame, Mustaqeem A. Siddiqui, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood (2020)
Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA
Authors: Sunisa Kongkiatkamon, Samuel Li, Tatiana Dombrovski, Laila Terkawi, Cassandra M Kerr, Vera Adema, Yasunobu Nagata, Wencke Walter, Hassan Awada, Bartlomiej Przychodzen, Stephan Hutter, Carmelo Gurnari, Simona Pagliuca, Manja Meggendorfer, Claudia Haferlach, Valeria Visconte, Torsten Haferlach, Jaroslaw P. Maciejewski, Thomas LaFramboise
Journal: Blood (2020)
Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro
Authors: Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, Karsten Spiekermann, Oliver Weigert, Sebastian Theurich, Michael von Bergwelt, Marion Subklewe
Journal: Blood (2020)
A Finale on EVALI?
Authors: Matthew Koslow, Irina Petrache
Journal: JAMA Network Open (2020)

Scott K. Aberegg, MD, MPH; Meghan M. Cirulis, MD; Sean D. Maddock, MD; Andrew Freeman, MD; Lynn M. Keenan, MD; Cheryl S. Pirozzi, MD, MS; Sanjeev M. Raman, MBBS, MD; Joyce Schroeder, MD; Howard Mann, MBBCh; Sean J. Callahan, MD
Cytosolic Ca<sup>2+</sup> transients during pulsed focused ultrasound generate reactive oxygen species and cause DNA damage in tumor cells
Authors: Robert B. Rosenblatt, Joseph A. Frank, Scott R. Burks
Journal: Theranostics (2020)

Mechanical forces from non-ablative pulsed focused ultrasound (pFUS) generate pro-inflammatory tumor microenvironments (TME), marked by increased cytokines, chemokines, and trophic factors, as well as immune cell infiltration and reduced tumor growth. pFUS also causes DNA damage within tumors, which is a potent activator of immunity and could contribute to changes in the TME. This study investigated mechanisms behind the mechanotransductive effects of pFUS causing DNA damage in several tumor cell types. Methods: 4T1 (murine breast tumor), B16 (murine melanoma), C6 (rat glioma), or MDA-MB-231 (human breast tumor) cells were sonicated in vitro (1.1MHz; 6MPa PNP; 10ms pulses; 10% duty cycle; 300 pulses). DNA damage was detected by TUNEL, apoptosis was measured by immunocytochemistry for cleaved caspase-3. Calcium, superoxide, and H2O2 were detected by fluorescent indicators and modulated by BAPTA-AM, mtTEMPOL, or Trolox, respectively. Results: pFUS increased TUNEL reactivity (range = 1.6-2.7-fold) in all cell types except C6 and did not induce apoptosis in any cell line. All lines displayed cytosolic Ca2+ transients during sonication. pFUS increased superoxide (range = 1.6-2.0-fold) and H2O2 (range = 2.3-2.8-fold) in all cell types except C6. BAPTA-AM blocked increased TUNEL reactivity, superoxide and H2O2 formation, while Trolox also blocked increased TUNEL reactivity increased after pFUS. mtTEMPOL allowed H2O2 formation and did not block increased TUNEL reactivity after pFUS. Unsonicated C6 cells had higher baseline concentrations of cytosolic Ca2+, superoxide, and H2O2, which were not associated with greater baseline TUNEL reactivity than the other cell lines. Conclusions: Mechanotransduction of pFUS directly induces DNA damage in tumor cells by cytosolic Ca2+ transients causing formation of superoxide and subsequently, H2O2. These results further suggest potential clinical utility for pFUS. However, the lack of pFUS-induced DNA damage in C6 cells demonstrates a range of potential tumor responses that may arise from physiological differences such as Ca2+ or redox homeostasis.
RNA Sequencing Analysis in Primary Mediastinal B Cell Lymphoma: Identification of Different Gene Expression Related to Chemoresistance
Authors: Guido Eugenio Parvis, Danny Incarnato, Davide Torti, Ubaldo Familiari, Francesco Vassallo, Giovanna Carrà, Salvatore Oliviero, Marco Volante, Angelo Guerrasio, Giuseppe Saglio, Alessandro Morotti
Journal: Blood (2020)
High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone
Authors: Sarah Farag, Ulrike Bacher, Myriam Legros, Daniel Betticher, Jean-Marc Lüthi, Thomas Egger, Thilo Zander, Barbara Jeker, Thomas Pabst
Journal: Blood (2020)
Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study
Authors: Steven W. Pipe, John Pasi, Toshko Lissitchkov, Margaret V. Ragni, Claude Négrier, Qifeng Yu, Stacey Poloskey, Baisong Mei, Shauna R. Andersson
Journal: Blood (2020)
Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Authors: Gilles Salles, Budhaditya Goswami, Vincenzo Bagnardi, Debarshi Dey, Mark Winderlich, Sumeet Ambarkhane, Dan Huang, Grzegorz S. Nowakowski
Journal: Blood (2020)
Response to CAR-T Therapy Can be Monitored Using Genome-Wide Sequencing of Cell-Free DNA in Patients with DLBCL
Authors: Aaron M Goodman, Kimberly A Holden, Ah-Reum Jeong, Lisa Kim, Kerry D Fitzgerald, Eyad Almasri, Graham McLennan, Marcia Eisenberg, Amin H Jahromi, Carl Hoh, Michael Hurley, Carolyn Mulroney, Dimitrios Tzachanis, Edward D. Ball, Taylor J Jensen, Razelle Kurzrock
Journal: Blood (2020)
Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project
Authors: Daniel Silva Nogueira, Marcia Torresan Delamain, Eliana Cristina Miranda, Yung Bruno de Melo Gonzaga, Juliana Pereira, Renata Lyrio, Marcelo Bellesso, Sergio Augusto B Brasil, Maria Almeida Dias, Rony Schaffel, Yana de Sousa Rabelo, Ademar Dantas Cunha, Thiago Xavier Carneiro, Abrahão Elias Hallack Neto, Nelson S Castro, Rafael Gaiolla, Suellen Ka Gi Mo, Talita Silveira, Massimo Federico, Jose Vassalo, Carmino Antonio Souza, Carlos Sérgio Chiattone
Journal: Blood (2020)
Abstract 540: Effects of Pro-inflammatory High Density Lipoprotein on Nrf2 Signalling and Foam Cell Formation in Macrophage of Coronary Artery Disease Patients
Authors: sini sunny, Jayakumari Narayani, Asokan Devarajan, Namakkal S. Rajasekaran
Journal: Circulation Research (2020)

Background: High density lipoprotein (HDL) from coronary artery disease (CAD) patients display proinflammatory properties, which persuades LDL oxidation and foam cell formation in monocytes/macrophages (Mo/MΦ). Nrf2/antioxidant signalling are crucial for maintaining the redox milieu, but these mechanisms are remain elusive in the setting of pro-inflammatory HDL ( pi HDL) mediated atherosclerosis and coronary artery disease (CAD). Methods: In healthy humans (n=20) and CAD patients (n=20), we assessed Nrf2 signalling, paraoxonase-1 activity, HDL function and foam cell formation in the circulating Mo/MΦ. Results: We observed a range of HDL activity (20-80%) in healthy humans, indicating that the HDL function varies among normal individuals. In comparison with functional HDL ( f HDL), pi HDL demonstrated decreased paraoxonase-1 activity (41.38±6.71 vs. 118.04±11.18; p&lt;0.05), higher levels of lipid peroxides (0.95±0.09 vs. 0.02±0.01; p&lt;0.05), higher triglyceride (75.4±6.79 vs. 31.76±4.19; p&lt;0.05) and phospholipid levels (74.09±5.9 vs. 46.47±6.11; p&lt;0.05) in CAD patients vs . healthy humans. Interestingly, we noticed an increase in MMP9 along with enhanced pi HDL in CAD patients, a previously unrecognized event, which might accelerate atherosclerosis in these individuals. Despite an increased Nrf2 nuclear translocation, we noticed significant decrease in the levels of antioxidant enzymes in the macrophages treated with pi HDL. It is likely that pi HDL mediated Nrf2 activation could be a compensatory response to ROS/oxidative stress in CAD patients, but insufficient antioxidant system might have resulted in enhanced foam cell formation. Conclusions: Taken together, these results suggest that pi HDL could be a key regulator of Nrf2 signalling in the Mo/MΦ of CAD patients. Thus, an early screening and identification of dysfunctional HDL (i.e. pi HDL) is crucial for vascular health, thereby preventing the progression of CAD.
Efficacy of Chemotherapeutic Regimens for Mantle Cell Lymphoma: A Systematic Review of Phase III Trials
Authors: Ali Jaan, Muhammad Tayyeb, Farhan Khalid, Muhammad Khawar Sana, Zahoor Ahmed, Muhammad Saad Farooqi, Mydah Sajid Hashmi, Syed Maaz Abdullah, Sundas Ali, Umar Farooque, Saad Javed, Hamid Ehsan, Faiz Anwer
Journal: Blood (2020)
Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma
Authors: Benjamin G Barwick, Vikas A. Gupta, Shannon M Matulis, Jonathan C Patton, Doris R Powell, Yanyan Gu, David L. Jaye, Karen N Conneely, Yin C Lin, Craig C Hofmeister, Ajay Nooka, Jonathan J Keats, Sagar Lonial, Paula M Vertino, Larry H. Boise
Journal: Blood (2020)
A Retrospective Analysis of Outcomes Following Allogeneic Stem Cell Transplantation for Patients from Appalachian Counties
Authors: Amneet Bajwa, Qiuhong Zhao, Joseph Coleman, Jonathan E Brammer, Hannah Choe, Yvonne A. Efebera, Karilyn Larkin, Alice S. Mims, Sam Penza, Ayman Saad, Sumithira Vasu, Sarah A Wall, Samantha Jaglowski
Journal: Blood (2020)